Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus statement

Angela Dispenzieri, S. Vincent Rajkumar, Morie A. Gertz, Rafael Fonseca, Martha Q. Lacy, P. Leif Bergsagel, Robert A. Kyle, Philip R. Greipp, Thomas E. Witzig, Craig B. Reeder, John A. Lust, Stephen J. Russell, Suzanne R. Hayman, Vivek Roy, Shaji Kumar, Steven R. Zeldenrust, Robert J. Dalton, A. Keith Stewart

Research output: Contribution to journalArticle

158 Scopus citations

Abstract

Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly 17,000 individuals and kills more than 11,000. Although no cure exists, many effective treatments are available that prolong survival and improve the quality of life of patients with this disease. The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, β2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment.

Original languageEnglish (US)
Pages (from-to)323-341
Number of pages19
JournalMayo Clinic proceedings
Volume82
Issue number3
DOIs
StatePublished - Mar 2007

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus statement'. Together they form a unique fingerprint.

  • Cite this